Awareness of acute myeloid leukaemia risk induced by diagnosis of a myelodysplastic syndrome

More efforts are needed to provide more systematic information about AML risk to patients wishing to know it. More research is needed to study if increasing awareness can lead to more active engagement of MDS patients in their care and can increase the rate of clinical trial participation.